- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02760264
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Melbourne, Australia
- Royal Children's Hospital
-
Westmead, Australia
- Sydney Children's Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
-
-
-
-
Petah Tikvah, Israel, 49202
- Schneider Children's Medical Center
-
-
-
-
-
Gothenburg, Sweden, 41685
- Queen Silvia Children's Hospital
-
-
-
-
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Newcastle upon Tyne Hospitals NHS Foundation Trust
-
-
-
-
California
-
Davis, California, United States, 95616
- University of California Davis
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
Orlando, Florida, United States, 32827
- Nemours Children's Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Texas
-
Dallas, Texas, United States, 75207
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject's parent or legal guardian has provided written informed consent/Health Insurance Portability and Accountability Act (HIPAA) authorization prior to any study-related procedures;
Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:
- Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR
- Identifiable mutation within the DMD gene (deletion/duplication of one or more exons) where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, OR
- Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein (i.e. nonsense mutation, deletion/duplication leading to a downstream stop codon), with a typical clinical picture of DMD;
- Subject is ≥ 4 years and < 7 years of age at time of enrollment in the study;
- Subject is able to complete the Time to Stand Test (TTSTAND) without assistance, as assessed at the Screening and Baseline Visits;
- Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not clinically significant, in the opinion of the Investigator. (Note: Serum gamma glutamyl transferase [GGT], creatinine, and total bilirubin all must be ≤ upper limit of the normal range at the Screening Visit);
- Subject has evidence of chicken pox immunity as determined by presence of IgG antibodies to varicella, as documented by a positive test result from the testing laboratory at the Screening Visit; and
- Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.
Exclusion Criteria:
- Subject has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;
- Subject has current or history of chronic systemic fungal or viral infections;
- Subject has had an acute illness within 4 weeks prior to the first dose of study medication;
- Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;
- Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary];
- Subject is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents. [Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
- Subject has used idebenone within 4 weeks prior to the first dose of study medication;
- Subject has an allergy or hypersensitivity to the study medication or to any of its constituents;
- Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
- Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;
- Subject is taking any other investigational drug currently or has taken any other investigational drug within 3 months prior to the start of study treatment; or
- Subject has previously been enrolled in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level Group 1
Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
|
Oral administration of 0.25 mg/kg/day daily for 14 days.
Other Names:
|
Experimental: Dose Level Group 2
Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
|
Oral administration of 0.75 mg/kg/day daily for 14 days.
Other Names:
|
Experimental: Dose Level Group 3
Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
|
Oral administration of 2.0 mg/kg/day daily for 14 days.
Other Names:
|
Experimental: Dose Level Group 4
Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
|
Oral administration of 6 mg/kg/day daily for 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03
Time Frame: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.
|
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug. Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group |
Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose
Time Frame: Baseline, Week 2
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline, Week 2
|
Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose
Time Frame: Baseline, Week 2
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline, Week 2
|
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin
Time Frame: Baseline , Week 2
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline , Week 2
|
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin
Time Frame: Baseline, Week 2
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline, Week 2
|
Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol
Time Frame: Week 2 (pre-dose)
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Week 2 (pre-dose)
|
Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin
Time Frame: Baseline, Day 1, Week 2, Week 4
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline, Day 1, Week 2, Week 4
|
Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide
Time Frame: Baseline Day 1 Week 2 Week 4
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline Day 1 Week 2 Week 4
|
Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide
Time Frame: Baseline, Day 1, Week 2, Week 4
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline, Day 1, Week 2, Week 4
|
Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides
Time Frame: Baseline, Day 1, Week 4
|
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
|
Baseline, Day 1, Week 4
|
Pharmacokinetic (PK) Assessments (Tmax)
Time Frame: Day 1, Week 2
|
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay.
tmax= time when plasma concentration is at maximum.
|
Day 1, Week 2
|
Pharmacokinetic (PK) Assessments (AUC Inf)
Time Frame: Day 1, Week 2
|
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay.
AUC inf= Area under the concentration vs. time curve to time infinity.
|
Day 1, Week 2
|
Pharmacokinetic (PK) Assessments CL (ml/hr/kg)
Time Frame: Day 1, Week 2
|
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
|
Day 1, Week 2
|
Pharmacokinetic (PK) Assessments t(1/2)
Time Frame: Day 1, Week 2
|
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay.
t1/2= elimination half life.
|
Day 1, Week 2
|
Pharmacokinetic (PK) Assessments (Cmax)
Time Frame: Day 1, Week 2
|
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
|
Day 1, Week 2
|
Metabolites in Safety Testing (MIST) Assessment
Time Frame: Week 2 (Day 14)
|
A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.
|
Week 2 (Day 14)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Paula R Clemens, MD, University of Pittsburgh
Publications and helpful links
General Publications
- Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM; CINRG VBP15 and DNHS Investigators. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020 Sep 21;17(9):e1003222. doi: 10.1371/journal.pmed.1003222. eCollection 2020 Sep.
- Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2020 Oct;60(10):1385-1396. doi: 10.1002/jcph.1632. Epub 2020 May 20.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VBP15-002
- 1R44NS095423-01 (U.S. NIH Grant/Contract)
- 1U34AR068616-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
-
Ondokuz Mayıs UniversityCompletedDuchenne Muscular Dystrophy (DMD)Turkey
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Parent Project, ItalyCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
GenethonInstitute of MyologyCompletedDuchenne Muscular Dystrophy (DMD)France
-
Ann & Robert H Lurie Children's Hospital of ChicagoChildren's National Research InstituteWithdrawnDuchenne Muscular Dystrophy (DMD)United States
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
Clinical Trials on Vamorolone 0.25 mg/kg/day
-
ReveraGen BioPharma, Inc.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
ReveraGen BioPharma, Inc.University of Pittsburgh; Cooperative International Neuromuscular Research...CompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
QED Therapeutics, Inc.Enrolling by invitationAchondroplasiaAustralia, United States, Argentina, Canada, France, Germany, Italy, Norway, Singapore, Spain, United Kingdom
-
PfizerTerminatedMultiple SclerosisUnited States
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Nangarhar UniversityCompletedVivax MalariaAfghanistan
-
Warner ChilcottCompleted
-
Hansa Biopharma ABUniversity College London HospitalsTerminatedPurpura, Thrombotic ThrombocytopenicUnited Kingdom
-
QED Therapeutics, Inc.RecruitingAchondroplasiaUnited States, Spain, United Kingdom, France, Canada, Australia
-
NeuroVive Pharmaceutical ABCompleted
-
University of California, San FranciscoBill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training... and other collaboratorsCompleted